These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 24359106)

  • 1. Effects of prostaglandin analogues on aqueous humor outflow pathways.
    Winkler NS; Fautsch MP
    J Ocul Pharmacol Ther; 2014; 30(2-3):102-9. PubMed ID: 24359106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting outflow facility in glaucoma management.
    Brubaker RF
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S17-20. PubMed ID: 12852430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuro-hormonal regulation of aqueous humor dynamics as the basis of glaucoma pharmacotherapy. Part II - Aqueous humor outflow].
    Terelak-Borys B; Liberek I
    Klin Oczna; 2007; 109(1-3):64-7. PubMed ID: 17687917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of prostaglandins on aqueous humour dynamics and intraocular pressure].
    Raber T
    Klin Monbl Augenheilkd; 2005 Oct; 222(10):802-6. PubMed ID: 16240273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility.
    Kiland JA; Gabelt BT; Kaufman PL
    Exp Eye Res; 2004 Mar; 78(3):639-51. PubMed ID: 15106944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prostaglandins on the aqueous humor outflow pathways.
    Weinreb RN; Toris CB; Gabelt BT; Lindsey JD; Kaufman PL
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S53-64. PubMed ID: 12204701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.
    Lim KS; Nau CB; O'Byrne MM; Hodge DO; Toris CB; McLaren JW; Johnson DH
    Ophthalmology; 2008 May; 115(5):790-795.e4. PubMed ID: 18452763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
    Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide: a drug target for glaucoma revisited.
    Garhöfer G; Schmetterer L
    Drug Discov Today; 2019 Aug; 24(8):1614-1620. PubMed ID: 31173910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinases and Glaucoma Treatment.
    Weinreb RN; Robinson MR; Dibas M; Stamer WD
    J Ocul Pharmacol Ther; 2020 May; 36(4):208-228. PubMed ID: 32233938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment.
    Johnson TV; Fan S; Zhan G; Camras CB; Toris CB
    J Glaucoma; 2010 Aug; 19(6):356-64. PubMed ID: 20179619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.
    Toris CB; Gabelt BT; Kaufman PL
    Surv Ophthalmol; 2008 Nov; 53 Suppl1(SUPPL1):S107-20. PubMed ID: 19038618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function.
    Toris CB; Camras CB; Yablonski ME; Brubaker RF
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S69-75. PubMed ID: 9154279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits.
    Toris CB; McLaughlin MA; Dworak DP; Fan S; Havens S; Zhan GL; Horan N; Prasanna G
    J Ocul Pharmacol Ther; 2016; 32(6):355-64. PubMed ID: 27266531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).
    Angeli A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):793-803. PubMed ID: 31462124
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of travoprost on aqueous humor dynamics in monkeys.
    Toris CB; Zhan GL; Camras CB; McLaughlin MA
    J Glaucoma; 2005 Feb; 14(1):70-3. PubMed ID: 15650608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapies for glaucoma.
    Toris CB
    Curr Mol Med; 2010 Dec; 10(9):824-40. PubMed ID: 21091423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological profiles of latanoprost (Xalatan), a novel anti-glaucoma drug].
    Nomura S; Hashimoto M
    Nihon Yakurigaku Zasshi; 2000 May; 115(5):280-6. PubMed ID: 10872179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.